Humana posted a 70-cent adjusted loss per share, yet raised its 2026 outlook.
Humana reported a 3Q26 adjusted loss of $0.70 per share, but raised its 2026 outlook. The company's GAAP EPS was $0.70 YTD, with an adjusted EPS of $16.84. Humana increased its FY 2026 adjusted EPS guidance to at least $9.50, up from $6.52. The company also announced growth in its CenterWell and Medicaid segments, as well as a joint venture with BlackRock.
How this was made
The 30-second read
Why it matters
Guidance upgrade could attract new buying interest and support the stock price.
Market read
Earnings and guidance update for a large‑cap insurer, relevant for health‑care investors.
What to watch
Potential headwinds from Medicaid enrollment costs and litigation expenses.
Background
Humana's 3Q26 earnings release includes GAAP loss, adjusted loss, and raised FY 2026 EPS guidance.
Ticker impact
Humana reported a 70‑cent adjusted loss per share but raised FY 2026 adjusted EPS guidance to at least $9.50, up from $9.00 previously.
likely upside as market prices in higher EPS expectations
Guidance raise for a large‑cap health insurer typically triggers buying pressure.
Market effects
May lift sentiment for the broader health‑insurance sector.
U.S. market focus on insurers could see modest gains.
Limited to U.S. equities; no direct global impact.
Counterpoint
If the loss per share concerns investors, the guidance raise may be viewed as insufficient.
Key entities
- companyHumana
U.S. health insurance provider.
